Navigation Links
Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab

Sphingomab Shows Near-Complete Mitigation of Choroidal Neovascularization (CNV) in an AMD Model

SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- Lpath, Inc. , the category leader in therapeutic agents against bioactive lipids, reported compelling proof-of-concept data in a standard animal model of human age-related macular degeneration (AMD).

The results were presented at the annual meeting of the Association of Research in Vision and Ophthalmology (ARVO) by Glenn L. Stoller, M.D., head of Lpath's ocular therapies division. Stoller reported that Lpath's lead drug candidate Sphingomab (in its humanized form) mitigated almost completely the choroidal neovascularization (CNV) formation in mice with laser-induced choroidal damage, which mimics the pathologic neovascularization experienced by patients with AMD.

Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator of angiogenesis (new blood-vessel growth), a process that has been strongly implicated in the progression of both AMD and cancer.

Moreover, S1P has recently garnered considerable attention in the scientific community as a validated mediator of fibrosis (scar-tissue formation), which contributes significantly to AMD-related vision loss. Lpath has demonstrated in previous studies that Sphingomab reduces scarring in a variety of organ systems by inhibiting S1P.

"This is the first demonstration that S1P is a mediator of CNV in an AMD model," said Stoller, "and that antibody-mediated inhibition of S1P is highly effective in preventing abnormal-blood-vessel growth beneath the retina."

Scott Pancoast, Lpath's president and CEO, added, "This near-complete mitigation of CNV establishes compelling pre-clinical efficacy for Sphingomab. Inhibition of S1P is a novel approach to treat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
Post Your Comments:
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
(Date:3/27/2015)... , March 27, 2015 A new report from ... America – Chile , ... are top targets for IVD firms.  The healthcare research firm ... into IVD strategies for the Latin American continent with a ... globally distributed supply operations. However, the country,s regional economic clout ...
(Date:3/27/2015)... , March 27, 2015 ... International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, ... senior service industry, will be held at Shanghai New ... On 25 February, 2015,  Implementation Suggestions on Encouraging Private ... Industry, which was jointly issued by the Ministry of ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6
... (telmisartan) against placebo, in reducing ... infarction, stroke and hospitalization for congestive heart ... receiving current standard of care, RIDGEFIELD, ... of the,TRANSCEND(TM)* trial demonstrated that treatment with ...
... Seven Korean medical centers to collaborate on studies of ... role of cell-mediated immunity, COLUMBIA, Md., Aug. 28 ... Woo Biotech, is delighted to be able to,announce our ... assay,for cell-mediated immunity at seven highly respected medical institutions,in ...
Cached Medicine Technology:TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 3TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 4TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 5TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 6TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 7Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3
(Date:3/27/2015)... 2015 The federal court overseeing thousands ... statin medication increases the risk that a patient will ... to Dismiss four individual cases that had been filed ... issued in the U.S. District Court, District of South ... dismissals were warranted because the plaintiffs in those claims ...
(Date:3/27/2015)... On February 21, 2015, Choices ... Stardust Penthouse on the rooftop of the luxurious ... sustainable product TV and film placement producer, was ... which featured some of the world’s top providers ... services. , “We were honored to have a ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
(Date:3/27/2015)... According to Health Day , on ... Abstinence Syndrome (NAS) are causing alarm for Florida officials. ... process for a month of their lives- and can ... vomiting. The condition is precipitated by drug use during ... (and employing medically assisted drug treatment) will also inflict ...
(Date:3/27/2015)... March 27, 2015 When struck with ... hard to know where to begin. The latest ... trucking accident attorney, offers accident victims a clear and ... assistance to ensure their personal injury claim is seen ... describing the first actions that should be taken immediately ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... 48, as Senior,Vice President and Chief Financial Officer. ... 20 years of executive,pharmaceutical experience in finance, operations, ... Chief Financial Officer for Watson,Mr. Durand will be ...
... of families with deployed Service members ... ... to the Oregon National Guard,s Emergency Relief fund, which,will support the needs of ... "TriWest made the contribution with the hope that we can make a,difference in ...
... Use of ABILIFY in Patients Ages 10 to 17 ... ... PRINCETON, N.J., Nov. 15 ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company ... for filing and granted a Priority Review to the supplemental New,Drug Application ...
... alternative for patients with erosive gastroesophageal reflux disease ... (GERD) who cannot swallow ... of Wyeth (NYSE: WYE ), announced today that the,U.S. ... Delayed-Release Oral Suspension, a new addition,to the Protonix family of ...
... Memphis PGA Tour Stop ... Jude, MEMPHIS, Tenn., Nov. 15 Stanford Financial Group CFO,James ... joined Tony,Thomas from St. Jude and Laurie Tucker, Senior Vice President ... from the,inaugural Stanford St. Jude Championship. The donation from the 2007 ...
Cached Medicine News:Health News:Low standards of child well-being linked to greater income inequality 2Health News:Watson Names Mark Durand Chief Financial Officer 2Health News:TriWest Contributes $30,000 to Oregon National Guard Fund 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 2Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 2Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 4
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This dissector offers dual-action jaws, which are long, tapered, and angled 30 to simplify even difficult laparoscopic dissection....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: